Clinical Trial Update: CMPA-GO Study: Growth and Safety Outcomes in Infants With CMPA Fed a Novel Extensively Hydrolyzed Formula [NA]

View source ↗

Summary

A clinical trial update on growth and safety outcomes in infants with cow's milk protein allergy fed a novel extensively hydrolyzed formula; the Nestlé SPN-spon…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cow Milk Protein Allergy

Drugs mentioned

• Novel extensively hydrolyzed formula for cow's milk protein allergy

Snippet

Sponsor: Société des Produits Nestlé (SPN) | Conditions: Cow Milk Protein Allergy | NA | Status: TERMINATED